Zacks: Analysts Anticipate Tcr2 Therapeutics Inc (NASDAQ:TCRR) to Post -$0.58 Earnings Per Share

Wall Street brokerages expect Tcr2 Therapeutics Inc (NASDAQ:TCRR) to announce ($0.58) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Tcr2 Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.43) and the lowest estimate coming in at ($0.64). Tcr2 Therapeutics reported earnings of ($0.46) per share during the same quarter last year, which would indicate a negative year over year growth rate of 26.1%. The firm is expected to announce its next quarterly earnings report on Thursday, August 13th.

According to Zacks, analysts expect that Tcr2 Therapeutics will report full-year earnings of ($2.47) per share for the current year, with EPS estimates ranging from ($2.86) to ($2.11). For the next year, analysts expect that the firm will report earnings of ($2.49) per share, with EPS estimates ranging from ($3.08) to ($1.98). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover Tcr2 Therapeutics.

Tcr2 Therapeutics (NASDAQ:TCRR) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.05).

TCRR has been the subject of a number of research analyst reports. ValuEngine raised shares of Tcr2 Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, February 12th. HC Wainwright reaffirmed a “buy” rating and set a $19.00 price objective on shares of Tcr2 Therapeutics in a research report on Monday, May 18th. BidaskClub raised shares of Tcr2 Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, May 24th. Wedbush reaffirmed an “outperform” rating on shares of Tcr2 Therapeutics in a research report on Monday, March 30th. Finally, Zacks Investment Research cut shares of Tcr2 Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $16.33.

In other Tcr2 Therapeutics news, Director Neil W. Gibson sold 17,723 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $6.60, for a total transaction of $116,971.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Neil W. Gibson sold 52,000 shares of the business’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $6.52, for a total value of $339,040.00. The disclosure for this sale can be found here. Insiders have sold 73,491 shares of company stock valued at $482,467 in the last ninety days. 39.07% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of TCRR. EcoR1 Capital LLC acquired a new position in Tcr2 Therapeutics during the fourth quarter worth about $3,420,000. ArrowMark Colorado Holdings LLC raised its stake in Tcr2 Therapeutics by 12.7% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 1,269,766 shares of the company’s stock worth $18,132,000 after acquiring an additional 143,459 shares in the last quarter. DAFNA Capital Management LLC acquired a new position in Tcr2 Therapeutics during the first quarter worth about $610,000. Victory Capital Management Inc. raised its stake in Tcr2 Therapeutics by 572.4% during the fourth quarter. Victory Capital Management Inc. now owns 86,432 shares of the company’s stock worth $1,234,000 after acquiring an additional 73,578 shares in the last quarter. Finally, Boston Private Wealth LLC acquired a new position in shares of Tcr2 Therapeutics in the fourth quarter valued at approximately $699,000. 59.22% of the stock is owned by hedge funds and other institutional investors.

TCRR stock traded down $0.10 during midday trading on Friday, reaching $10.10. 112,520 shares of the company were exchanged, compared to its average volume of 102,721. The business has a 50-day moving average price of $10.08 and a two-hundred day moving average price of $12.66. Tcr2 Therapeutics has a one year low of $5.84 and a one year high of $21.06. The firm has a market capitalization of $243.17 million, a price-to-earnings ratio of -4.53 and a beta of 1.76.

About Tcr2 Therapeutics

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

Further Reading: Is it better to buy a fund with a higher or lower NAV?

Get a free copy of the Zacks research report on Tcr2 Therapeutics (TCRR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tcr2 Therapeutics (NASDAQ:TCRR)

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.